Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyNovember 19, 2026

Congressional Commission Warns US Pharma Depends on China Biotech

The National Security Commission on Emerging Biotechnology, a congressional body, warned in a Nov. 18 brief that China is working to control the pharmaceutical supply chain from manufacturing to drug discovery, and that U.S. drugmakers' growing licensing deals with Chinese biotechs are deepening American dependence. The commission said China published a pharmaceutical-focused follow-on to its 15th Five-Year Plan in September setting 2030 goals for more first-in-class drugs and global sales, and analyzed 57 deals between the 15 largest U.S. drugmakers and 42 Chinese biotechs from January 2023 to October 2026, finding rising up-front payments and escalating deal structures. It pointed to China's October proposal, not yet final, to restrict exports of certain next-generation biopharmaceutical technologies. The brief noted the FDA this month rejected a Chinese-invented lung cancer drug, and that generic drugs rely primarily on India and China for active ingredients while the U.S. accounts for only 12% of production.

Why it mattersState Medicaid agencies and health plans that manage pharmacy benefits could face supply disruptions or shortages of sterile injectable generics if reliance on Chinese-sourced active ingredients and drug discovery platforms continues unaddressed.

Pharmacy

Read the full article at beckershospitalreview.com →
Also covered by:healthcaredive.com
Share this briefing

You might also like

← All stories

Get the daily briefing.